fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Advertisment

Phase III LOTUS study of Stelara in Systemic Lupus Erythematosus discontinued.- Janssen Pharma

Written by | 29 Jun 2020 | Pharmacy

The Janssen Pharmaceutical Companies of Johnson & Johnson announced its decision to discontinue the Phase III LOTUS study of Stelara (ustekinumab) in Systemic Lupus Erythematosus (SLE) due to lack of efficacy in SLE. The decision is based on data from a pre-planned interim efficacy analysis.

Interim safety findings were consistent with the known safety profile of Stelara, and no new safety signals were identified. Investigators, study participants and health authorities have been informed of the decision. The company intends to thoroughly analyze the totality of the study data and publish findings.

“Lupus patients are waiting for better treatments, which makes this outcome disappointing,” said Alyssa Johnsen, M.D., Ph.D., Vice President, Rheumatology Disease Area Leader, Janssen Research & Development, LLC. “Our hope is that by ultimately sharing these data with the scientific community we can help inform lupus research and therefore still have a positive impact on the lives of patients living with SLE. Janssen continues to be strongly committed to research and development of novel therapies for lupus.” The decision to discontinue the LOTUS study does not impact any other ongoing studies with ustekinumab or current indications. A second Phase III study, LOTUS-C, in SLE to be conducted in China was planned but will not start given this decision.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.